While umbilical cord blood transplantation (UCBT) provides an alternative donor graft source for patients without HLA matched donors, 1 it is associated with delayed immune reconstitution and increased risk of infection. 1, 2 Although Mycobacterium tuberculosis (TB) infection is uncommon in UCBT recipients, few available reports [3] [4] [5] suggest a more severe clinical course as compared with the TB infections in auto-and allo-SCT recipients. [6] [7] [8] Here, we report a case of TB following UCBT and discuss its clinical characteristics and challenges.
A 69-year-old man was admitted to our hospital with a fever 39.2°C and chills on day 50 following UCBT. His history was significant for AML diagnosed in May 2011 with the initial presentation of WBC 83x10 3 /mL, platelet 55x10 3 /mL and 86% blasts. His AML was FLT3 mutation negative but NPM1 mutation positive. He received '7+3' Ara-C plus DNR induction therapy followed by three courses of high-dose Ara-C consolidation. He achieved a CR to induction but relapsed in February 2013 and received re-induction with the FLAG-IDA regimen, achieving a second CR with o 5% blasts on a day-14 marrow. Post-remission consolidation consisted of one cycle of decitabine and a cycle of CY. He was conditioned with Flu/Cy/TBI and received a double unit UCBT on 08 August 2013 (Table 1 : Patient 6).
He had giardia diarrhea at day 15 post transplant for which he received a course of metronidazole and had CMV reactivation on day 21, which was treated with ganciclovir and oral valganciclovir with four weekly doses of i.v. Ig. He had no significant history of infection including TB, and his pre-transplantation screening was negative for HSV, hepatitis A, B and C, HTLV1/2, HIV, toxoplasmosis and syphilis. A pre-transplant chest computed tomography (CT) scan showed bilateral linear scarring and very mild ground-glass opacity, interpreted as 'atelectasis without evidence for acute infection'. He had been born in Acapulco, Mexico but had lived in the USA for more than 50 years. He had no significant history of infection in his family.
He was treated with cefipime on day 1 post-admission with pan-cultures sent and CMV, HH6 titers requested. His CT chest and sinus were unremarkable on day 3 and vancomycin was started for ongoing fever. Because of the diarrhea and positive PCR result for Clostridium difficile, he was switched to oral vancomycin and metronidazole. On day 7, owing to the persistent fever and CT abdomen showing multiple hypo-densities in the spleen suggestive of micro-abscesses secondary to candida infection, he was treated with micafungin. He continued to have high spiking fevers with blood cultures negative for bacterial infection x5 and negative PCR tests for CMV, EBV and HHV6. Due to worsening liver enzymes, GVHD was considered in the differential diagnosis of his diarrhea but a colonoscopy could not be performed because of severe thrombocytopenia and his deteriorating clinical condition. Venous occlusive disease was considered, but the patient had no hepatomegaly and both MRI and ultrasound showed patent hepatic vessels. His lab results were consistent with severe disseminated intravascular coagulation. On day 13 of admission he became hypotensive and tachypneic. He was intubated and sent to ICU. Antibiotics were changed to amphotericin, meropenem and daptomycin, and he expired on day 16 of admission, 66 days after his UCBT. An acid-fast bacilli (AFB) culture sent on day 10 was reported as positive for TB on day 40 after admission. An autopsy showed 'disseminated M. tuberculosis with involvement of the lungs, lymph nodes, liver, spleen and BM'.
By using the search term/s ('tuberculosis/TB' + 'cord' + 'transplant/transplantation'), followed by a manual selection, we identified possibly all the reported cases of TB in UCBT recipients. Only seven patients were identified (Table 1 , including the patient presented here, labeled as 'Patient 6'). Except for 'Patient 7', who was diagnosed with localized TB more than 4 years post transplant and was off immuno-suppressive drug therapy, 9 TB presented in disseminated form and occurred within the first 100 days after cord blood transplantation (median onset of~50 days post transplant) in other patients. In addition, the mortality rate was extremely high in five out of six cases. The only surviving patient was the youngest in the series (age 20). The clinical course of TB in recipients of UCBT is therefore very different from TB in other hematopoietic SCT (HSCT) recipients. Whereas the median TB onset time in auto-and allo-SCT recipients is about 279 and 257 days, respectively, 6, 7 it is only about 50 days in UCBT recipients; on the basis of the data extracted from the literature. In addition, in either autologous or allogeneic recipients, TB tends to be localized and mainly involves the lungs, whereas in UCBT recipients TB is almost all disseminated with very high mortality. The delayed immune reconstitution, especially the reconstitution of T-cell subsets in the first 100 days, 2 along with other factors including conditioning regimen, immunosuppressants and so on could potentially explain why TB in UCBT recipients has much earlier onset and presents clinically in a more fulminant form with systemic dissemination.
Early diagnosis of TB is crucial for management, but can be challenging in severely immunocompromised patients, such as UCBT recipients, in whom TB may present differently. 8 In addition, although mycobacteria culture is the gold standard in the setting of conventional TB, culture results may be reported too late to manage disseminated TB-as happened to our patient. AFB staining is fast, but it has low sensitivity and requires isolation of a site-specific specimen which can be difficult to obtain (for example, no sputum production); or requires invasive diagnostic tests and biopsies that may be risky owing to the severe BM suppression (anemia, neutropenia and thrombocytopenia). PCR using peripheral blood to detect the TB DNA is therefore an attractive strategy because it is fast and highly specific. Table 2 is a list of studies that used blood PCR with various modifications for the early diagnosis of TB. Those studies suggest that detection of TB via PCR of the peripheral blood has universally very high specificity (median495%), but different levels of sensitivity. It appears that the sensitivity varies with the PCR targeting sequence (IS6110 vs others), location of the disease (pulmonary vs extrapulmonary) and patients' immune status (HIV and immunosuppressed vs normal). It demonstrates the trend of high yield if we use PCR primers targeting IS6110 sequence in immunosuppressed patients with extra-pulmonary TB, and the sensitivity may get further enhancement if we target MPB64 as well in multiplex nested PCR along with modifications of DNA extraction and Letter to the Editor Table 2 . Letter to the Editor purification. 10 As UCBT recipients are immunosuppressed for at least the first 100 days post transplant, 1, 2 and almost all UCBT recipients present with disseminated disease, [3] [4] [5] PCR of TB from peripheral blood may offer an alternative approach for a more rapid, antemortem diagnosis, especially when obtaining the sitespecific specimens is difficult.
Another challenging issue is the pre-transplantation screening to identify patients with latent TB infection prior to UCBT. Interestingly, a tuberculin skin test (TST or PPD test) is not part of the routine screening test in BMT clinical trials, nor a required test at Emory BMT Center, arguably because prior BCG (Bacillus Calmette-Guerin) vaccination can result in a false positive test and a normal CT chest (regardless of PPD test result) is sufficient to permit a patient to proceed to transplantation. In accordance with this, the ASBMT (American Society for Blood and Marrow Transplantation) guideline disagreed about obtaining a TST in every transplant candidate, 11 however, it did recommend that if the TST is positive, but no active TB identified, 'treatment for latent TB infection should be initiated but the HSCT need not be delayed'. 11 For the case presented here, if the patient's TST had been positive, the bilateral linear scarring and very mild groundglass opacity seen on the chest CT might have not been interpreted as 'negative', and treatment for latent TB infection could have been considered. Alternatively, the IFN-γ release assay (IGRA) such as the QuantiFERON-TB Gold In-Tube test (QFT-GIT) may be used as it has been shown to be more effective in identifying latent TB infection in immunocompromised patients 12, 13 and certain organ transplant recipients. 14 A recently completed clinical trial (NCT01021124) estimating the usefulness of QFT-GIT in HSCT recipients, based on 391 patients in South Korea, also demonstrated that IGRA is a more sensitive and specific test for predicting active TB after HSCT than the TST. 15 In summary, owing to delayed cellular immune reconstitution, UCBT recipients who have reactivation of latent TB have an earlier onset of clinical infection, very high mortality and present with disseminated disease. It is therefore important to consider TB in the differential diagnosis of fever of unknown origin in UCBT recipients, particularly those with a social or family history that suggests a possible history of TB exposure. We propose here that early detection via PCR of peripheral blood may offer practical value to identify active TB infection in selected population, and that the use of IGRA as a screening test before transplant should be considered, especially in high-risk populations.
